I'll add: We have to keep in mind that Macfarlane, Kornhauser et al are human. They are hopeful about being part of a cure discovery, they are making income doing these studies, they want to encourage enrollment, they want to help. They are, like everyone, vulnerable to bias, and can misstep.
These participants no doubt are feeling better. Whether they are truly getting verifiable effects distinguishable from placebo and from all placebo effects (everyone understands they are related but not the same thing?) cannot be judged from anecdote. We need to complete this large, controlled, 48 week trial.
What these researchers have said is nice to hear, but it indicates proper trial blinding protocol is not being strictly followed, not that 2-73 is "working". We keep our fingers crossed on that.
Market Data 
Markets 
AI
